TIGIT and neuroblastoma: To further improve the antitumor efficacy of GD2-directed immunotherapies against high-risk neuroblastoma (NB), we investigated, in the present work, a combinatorial immunotherapy, with the chimeric antibody (Ab) dinutuximab beta (DB) and the double immune checkpoint blockade of T-cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) and programmed cell death ligand-1 (PD-L1).